ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentAu ZhAraris Biotech AG
Araris Biotech AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Araris Biotech AG develops a proprietary linker technology for antibody–drug conjugates (ADCs) that enables one‑step enzymatic attachment of payloads to off‑the‑shelf antibodies without antibody re‑engineering. The platform targets a specific site (Q295) in the IgG‑Fc region to produce homogeneous, stable and water‑soluble ADCs, and the company advances an internal ADC pipeline while collaborating with external partners.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Araris Biotech AG

✓ Offered4
ADC Linker Technology (AraLinQ®)
Peptide linker technology for site-specific conjugation of payloads to antibodies, one-step with „off-the-shelf“ antibodies; developed for stable, homogeneous and highly soluble Antibody-Drug Conjugates.
Development of Antibody-Drug Conjugates (ADCs)
Development of Antibody-Drug Conjugates for targeted delivery of active substances to cancer cells, with a focus on preclinical and clinical candidates.
ADC Pipeline Programs
Own ADC programs in Discovery, preclinical and Phase 1, including ARC-02 against CD79b as well as ARC-401 against Nectin-4 and ARC-201 against NaPi2b.
Research collaborations and licensing of ADC technology
Research collaborations as well as option and licensing agreements for the development of new ADCs with partners using the AraLinQ™ technology.
Trust & reputation

ranQ Trust Score of Araris Biotech AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Araris Biotech AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Araris Biotech AG scores 74.8 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Araris Biotech AG scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Araris Biotech AG scores 62.4 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.91.44%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.33.34%
Qualifications+0.00

Araris Biotech AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

March 20, 2025Media
Bei mehr als eine Milliarde Umsatz: Das PSI-Spin-off Araris Biotech AG erreicht Bewertung auf Unicorn-Level
aargauerzeitung.ch
March 17, 2025Media
Taiho Pharmaceutical to acquire Araris Biotech for up to USD 1.1 billion
startupticker.ch
April 18, 2023Media
Araris expands its pipeline towards solid tumor indications
startupticker.ch

Knowledge

No knowledge articles yet

Once Araris Biotech AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Araris Biotech AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Araris Biotech AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Araris Biotech AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Riedhofstrasse 11
8804 Au Zh

At a glance

Legal form
Corporation
UID
CHE-134.399.290
Founded
2019 · 7 years
Last commercial register change
May 7, 2025
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    NT
    Numab Therapeutics AG
    Horgen
    FP
    Fahrländer Partner AG
    Zurich
    FP
    Fahrländer Partner Raumentwicklung AG
    Zurich
    II
    IIS Institute for Independent Studies Zürich GmbH
    Zurich
    MA
    Mabylon AG
    Schlieren
    NS
    Neurimmune Subone AG
    Schlieren
    LA
    Lock and Key Biosciences GmbH
    Meilen
    LI
    Ludwig Institut für Krebsforschung AG
    Zurich